European S3-guidelines on the systemic treatment of psoriasis vulgaris

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue SUPPL. 2, 2009, Pages 1-70

  Pathirana, D ^a   Ormerod, A D ^b   Saiag, P ^c   Smith, C ^d   Spuls, P I ^e   Nast, A ^a   Barker, J ^f   Bos, J D ^g   Burmester, G R ^w   Chimenti, S ^h   Dubertret, L ⁱ   Eberlein, B ^q   Erdmann, R ^a   Ferguson, J ^j   Girolomoni, G ^r   Gisondi, P ^x   Giunta, A ^h   Griffiths, C ^k   Honigsmann H ^s   Hussain, M ^a   Jobling, R ^y   Karvonen, S L ^l   Kemeny, L ^t   Kopp, I ^ae   Leonardi, C ^z   MacCarone, M ^aa   Menter, A ^ab   Mrowietz, U ^u   Naldi, L ^m   Nijsten, T ^ac   Ortonne, J P ⁿ   Orzechowski, H D ^w   Rantanen, T ^o   Reich, K ^v   Reytan, N ^a   Richards, H ^ad   Thio, H B ^ac   Van De Kerkhof, P ^p   Rzany, B ^w   more..

^a Division of Evidence Based Medicine (dEBM)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j UNIVERSITY OF DUNDEE   (United Kingdom)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m OSPEDALI RIUNITI   (Italy)

ⁿ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^o PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^r UNIVERSITY HOSPITAL OF VERONA   (Italy)

^s MEDICAL UNIVERSITY OF VIENNA   (Austria)

^t UNIVERSITY OF SZEGED   (Hungary)

^u UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^v DERMATOLOGIKUM HAMBURG   (Germany)

^w CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^x UNIVERSITY OF VERONA   (Italy)

^y ST JOHN S COLLEGE   (United Kingdom)

^z Central Dermatology   (United States)

^aa PA ^*  (Italy)

^ab Texas Dermatology Associates PA   (United States)

^ac ERASMUS MEDICAL CENTER   (Netherlands)

^ad MERCY UNIVERSITY HOSPITAL   (Ireland)

^ae PHILIPPS UNIVERSITY MARBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CALCIPOTRIOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMPHENICOL; COLCHICINE; COTRIMOXAZOLE; CYCLOSPORIN A; CYTOSTATIC AGENT; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; EZETIMIBE; FOLIC ACID; FUMADERM; FUMARIC ACID DERIVATIVE; INFLIXIMAB; ISOTRETINOIN; LEFLUNOMIDE; MAGNESIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENYTOIN; PHOTOSENSITIZING AGENT; PROBENECID; PYRIMETHAMINE; RETINOID; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; USTEKINUMAB; CYCLOSPORIN; DERMATOLOGICAL AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL CRAMP; ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANTIHYPERTENSIVE THERAPY; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; ATAXIA; BACTERIAL ARTHRITIS; BILIRUBIN BLOOD LEVEL; BONE; BONE MARROW SUPPRESSION; BONE PAIN; BREAST FEEDING; BRONCHITIS; BURNING SENSATION; CD4 LYMPHOCYTE COUNT; CELLULITIS; CHEILITIS; CHILL; CLINICAL TRIAL; COLITIS; COLOR VISION; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMYELINATING DISEASE; DEPRESSION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIVERTICULITIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; ERYSIPELAS; ERYTHEMA; FATIGUE; FATTY LIVER; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HEARING IMPAIRMENT; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; INTRACRANIAL HYPERTENSION; ISCHEMIC HEART DISEASE; JAUNDICE; KIDNEY FAILURE; KIDNEY INJURY; LEUKOCYTOSIS; LEUKOPENIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LOADING DRUG DOSE; LUNG ALVEOLITIS; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; LYMPHOMA; MAGNESIUM BLOOD LEVEL; MALAISE; MEDICAL PRACTICE; MONOTHERAPY; MOTOR NEUROPATHY; MYALGIA; MYOPATHY; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NIGHT VISION; OPPORTUNISTIC INFECTION; PANCREATITIS; PANCYTOPENIA; PAPILLEDEMA; PARESTHESIA; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PHOTOTHERAPY; PNEUMONIA; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PURINE SYNTHESIS; PUVA; PYELONEPHRITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REMISSION; RHEUMATOID ARTHRITIS; SEIZURE; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN CANCER; SKIN INFECTION; SKIN NECROSIS; SQUAMOUS CELL CARCINOMA; SURGICAL INFECTION; SYSTEMIC THERAPY; TACHYPHYLAXIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREMOR; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; URTICARIA; VASCULITIS; VISION; VOMITING; WEIGHT GAIN; XEROSIS;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; PSORIASIS; PUVA THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RETINOIDS;

EID: 70249137988     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03389.x     Document Type: Article

References (264)

1. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996 135 : 533 537.
2. Schmid-Ott G, Malewski P, Kreiselmaier I et al. [Psychosocial consequences of psoriasis - an empirical study of disease burden in 3753 affected people]. Hautarzt 2005 56 : 466 472.
3. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 407.
4. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004 9 : 136 139.
5. Richards HL, Fortune DG, O'Sullivan TM et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999 41 : 581 583.
6. Nast A, Erdmann R, Pathirana D et al. Translating psoriasis treatment guidelines into clinical practice - the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract 2008 14 : 803 806.
7. Nederlandse Verenigung voor Dermatologie en Venerologie (NVDV) and Institute for Healthcare Improvement (CBO). Dutch Guideline for the treatment of severe psoriasis (ultraviolet B, ultraviolet A in combination with oral psoralen, cyclosporin A, methotrexate and acitretine). Van Zuiden Communications, 2003.
8. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 58 : 826 850.
9. Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007 299 : 111 138. (Pubitemid 46835379)
10. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
11. Spuls PI, Tuut MK, van Everdingen JJ et al. The practice guideline 'Photo (chemo) therapy and systemic therapy in severe chronic plaque-psoriasis'. Ned Tijdschr Geneeskd 2004 148 : 2121 2125.
12. Augustin M, Kruger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008 216 : 366 372.
13. Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006 155 : 729 736.
14. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 : 280 284.
15. Nast A, Reytan N, Rosumeck S et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008 22 : 1337 1342.
16. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 244.
17. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152 : 861 867.
18. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007 5 : 566 574.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
20. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005 125 : 659 664.
21. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002 147 (Suppl. 62 50.
22. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007 156 : 945 950.
23. Nast A, Spuls PI, Ormerod A et al. A critical appraisal of evidence based guidelines for the treatment of psoriasis vulgaris - 'AGREE-ing' on a common base for European evidence based Psoriasis Treatment Guidelines. J Eur Acad Dermatol Venereol 2009 Feb 24. [Epub ahead of print] DOI
24. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 1741.
25. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004 19 : 225 230.
26. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 143 : 1493 1499.
27. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007 80 : 273 290.
28. Reich K, Mossner R, Konig IR et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002 118 : 155 163.
29. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007 143 : 1559 1565.
30. Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999 135 : 1479 1484.
31. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007 120 : 953 959.
32. Nast A, Kopp IB, Augustin M et al. [S3-guidelines for the therapy of psoriasis vulgaris]. J Dtsch Dermatol Ges 2006 4 (Suppl. 2 S1 S126.
33. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005 23 : 681 694.
34. Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000 143 : 983 991.
35. Richards HL, Fortune DG, Chong SL et al. Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol 2004 123 : 49 56.
36. Akay A, Pekcanlar A, Bozdag KE et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002 16 : 347 352.
37. Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression. Dermatology 2006 212 : 123 127.
38. Richards HL, Fortune DG, Griffiths CE et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001 50 : 11 15.
39. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998 139 : 846 850.
40. Wahl A, Loge JH, Wiklund I et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000 43 : 803 808.
41. Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999 141 : 1067 1075.
42. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997 36 : 259 262.
43. Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 1998 61 : 339 342.
44. Vardy D, Besser A, Amir M et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002 147 : 736 742.
45. Leary MR, Rapp SR, Herbst KC et al. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol 1998 17 : 530 536.
46. Fortune DG, Richards HL, Kirby B et al. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol 2004 151 : 1219 1226.
47. Evers AW, Lu Y, Duller P et al. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol 2005 152 : 1275 1281.
48. Fortune DG, Richards HL, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003 139 : 752 756.
49. Fortune DG, Richards HL, Griffiths CE et al. Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. Br J Clin Psychol 2004 43 : 65 82.
50. Fortune DG, Richards HL, Kirby B et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002 146 : 458 465.
51. Kabat-Zinn J, Wheeler E, Light T et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 1998 60 : 625 632.
52. Fortune DG, Richards HL, Main CJ et al. Developing clinical psychology services in an outpatient dermatology specialist clinic: what factors are associatedwith non-uptake of the service? Clin Psychol Forum 1998 115 : 34 36.
53. Richards HL, Fortune DG, Weidmann A et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004 151 : 1227 1233.
54. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958 78 : 200 203.
55. Smith KC. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett 2000 6 : 1 2 5.
56. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971 103 : 33 38.
57. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993 28 : 466 469.
58. Ortiz Z, Shea B, Suarez Almazor M et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000 CD000951.
59. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001 44 : 1515 1524.
60. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006 54 : 1013 1018.
61. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 349 : 658 665.
62. Morison WL, Momtaz K, Parrish JA et al. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982 6 : 46 51.
63. Nyfors A, Brodthagen H. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970 140 : 345 355.
64. Paul BS, Momtaz K, Stern RS et al. Combined methotrexate - ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982 7 : 758 762.
65. Newman M, Auerbach R, Feiner H et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989 125 : 1218 1224.
66. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 : 711 716.
67. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005 152 : 444 450.
68. Maurice PD, Maddox AJ, Green CA et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005 152 : 451 458.
69. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001 144 : 100 103.
70. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004 150 : 741 746.
71. Müller W, Hermann B. Beeinflussung der Psoriasis durch Cyclosporin A. Dtsch Med Wochenschr 1979 104 : 1047.
72. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998 139 : 88 95.
73. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004 151 (Suppl. 69 3 17.
74. Nakayama J, Hori Y, Nakagawa H et al. Comparison of two therapeutic regimens, continous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A. Eur J Dermatol 1996 6 : 341 343.
75. Powles AV, Baker BS, McFadden J et al. Intralesional injection of cyclosporin in psoriasis. Lancet 1988 1 : 537.
76. Powles AV, Baker BS, McFadden JP et al. Intralesional cyclosporin in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989 146 : 148 149 discussion 49-50.
77. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993 14 : 69 74.
78. Thaci D, Brautigam M, Kaufmann R et al. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 2002 205 : 383 388.
79. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001 44 : 643 651.
80. Mahrle G, Schulze HJ, Farber L et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995 32 : 78 88.
81. Elder CA, Moore M, Chang CT et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995 35 : 865 875.
82. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991 324 : 277 284.
83. Engst R, Huber J. [Results of cyclosporin treatment of severe, chronic psoriasis vulgaris]. Hautarzt 1989 40 : 486 489.
84. Finzi AF, Mozzanica N, Cattaneo A et al. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989 21 : 91 97.
85. Finzi AF, Mozzanica N, Pigatto PD et al. Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology 1993 187 : 8 18.
86. Franchi C, Cainelli G, Frigerio E et al. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 2004 17 : 401 406.
87. Grossman RM, Thivolet J, Claudy A et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994 31 : 68 74.
88. Higgins E, Munro C, Marks J et al. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 1989 121 : 71 74.
89. Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994 130 : 366 375.
90. Levell NJ, Shuster S, Munro CS et al. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995 75 : 65 69.
91. Meffert H, Brautigam M, Farber L et al. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997 77 : 137 141.
92. Petzelbauer P, Honigsmann H, Langer K et al. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 1990 123 : 641 647.
93. Reitamo S, Spuls P, Sassolas B et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001 145 : 438 445.
94. Grossman RM, Chevret S, Abi-Rached J et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996 132 : 623 629.
95. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001 358 : 1042 1045.
96. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003 120 : 211 216.
97. Agnew KL, Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol 2003 17 : 113 114.
98. van de Kerkhof PC, Cambazard F, Hutchinson PE et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998 138 : 84 89. (Pubitemid 28077942)
99. Mrowietz U. Ciclosporin in der Dermatologie. Georg Thieme Verlag Stuttgart, New York, 2003.
100. Griffiths CE, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004 150 (Suppl. 67 11 23.
101. Kaoukhov A, Paul C, Lahfa M et al. [Renal function during long-term cyclosporin treatment of psoriasis]. Ann Dermatol Venereol 2000 127 : 180 183.
102. Yuan J, Zhou J, Chen BC et al. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc 2005 37 : 1892 1895.
103. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985 121 : 1297 1301.
104. Gollnick H, Bauer R, Brindley C et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988 19 : 458 468.
105. Kragballe K, Jansen CT, Geiger JM et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 1989 69 : 35 40.
106. Ledo A, Martin M, Geiger JM et al. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate. Int J Dermatol 1988 27 : 656 660.
107. Meffert H, Sonnichsen N. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate. Acta Derm Venereol Suppl (Stockh) 1989 146 : 176 177.
108. Goldfarb MT, Ellis CN, Gupta AK et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988 18 : 655 662.
109. Young HS, Summers AM, Read IR et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006 126 : 453 459.
110. Mucida D, Park Y, Kim G et al. Reciprocal TH17 and regulatory T-cell differentiation mediated by retinoic acid. Science 2007 317 : 256 260.
111. Gollnick HP, Dummler U. Retinoids. Clin Dermatol 1997 15 : 799 810.
112. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999 41 : S22 S24.
113. Murray HE, Anhalt AW, Lessard R et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991 24 : 598 602.
114. Caca-Biljanovska NG, V'Lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 2002 43 : 707 712.
115. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 2003 139 : 436 442.
116. Gupta AK, Goldfarb MT, Ellis CN et al. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989 20 : 1088 1093.
117. Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989 121 : 107 112. (Pubitemid 19177127)
118. Saurat JH, Geiger JM, Amblard P et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988 177 : 218 224.
119. Berbis P, Geiger JM, Vaisse C et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989 178 : 88 92.
120. Lowe NJ, Prystowsky JH, Bourget T et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991 24 : 591 594.
121. Gronhoj Larsen F, Steinkjer B, Jakobsen P et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000 143 : 1164 1169.
122. Gisondi P, Del Giglio M, Cotena C et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008 158 : 1345 1349.
123. Conley J, Nanton J, Dhawan S et al. Novel combination regimens: biologics and acitretin for the treatment of psoriasis - a case series. J Dermatolog Treat 2006 17 : 86 89.
124. Altmeyer P, Hartwig R, Matthes U. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients]. Hautarzt 1996 47 : 190 196.
125. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994 30 : 977 981.
126. Bayard W, Hunziker T, Krebs A et al. [Peroral long-term treatment of psoriasis using fumaric acid derivatives]. Hautarzt 1987 38 : 279 285.
127. Carboni I, De Felice C, De Simoni I et al. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 2004 15 : 23 26.
128. Gollnick H, Altmeyer P, Kaufmann R et al. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 2002 205 : 46 53.
129. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992 27 : 769 771.
130. Litjens NH, Nibbering PH, Barrois AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003 148 : 444 451.
131. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998 138 : 456 460.
132. Nugteren-Huying WM, van der Schroeff JG, Hermans J et al. [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study]. Ned Tijdschr Geneeskd 1990 134 : 2387 2391.
133. Hoefnagel JJ, Thio HB, Willemze R et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003 149 : 363 369.
134. U.S. Food and Drug administration. Full prescribing information, Humira (adalimumab). 2008. Available at: http://www.fda.gov/cder/foi/label/2008/ 125057s114lbl.pdf.
135. European Medicines Agency. Summary of product characteristics, Humira 40 mg solution for injection. 2008. Available at: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/humira/H-481-PI-en.pdf.
136. Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008 117 : 244 279.
137. Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag 2008 4 : 345 351.
138. Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008 : Jul 11.
139. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
140. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
141. Abbott Laboratories Ltd. Fachinformation Humira 40 mg Injektionslösung in Fertigspritze 2008. Available at: http://www.fachinfo. de/data/fi/jsearch?praep.
142. Martinez LC, Harrison-Balestra C, Caeiro JP et al. The role of the QuantiFERON-TB Gold test as screening prior to administration of tumor necrosis factor inhibitors. Arch Dermatol 2007 143 : 809 810.
143. Hannuksela-Svahn A, Pukkala E, Laara E et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000 114 : 587 590.
144. Smith EC, Riddle C, Menter MA et al. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008 47 : 514 518.
145. Nestorov I, Zitnik R, DeVries T et al. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 2006 62 : 435 445.
146. Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 56 : 598 603.
147. Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006 10 : 1 233, i iv.
148. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 1632 discussion 32.
149. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 2022.
150. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 1312.
151. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006 367 : 29 35.
152. Cassano N, Loconsole F, Galluccio A et al. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol 2006 19 : 225 229.
153. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 143 : 719 726.
154. Costanzo A, Mazzotta A, Papoutsaki M et al. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005 152 : 187 189.
155. Stern RS, Nijsten T. Insuring rapid and robust safety assessment. J Invest Dermatol 2004 122 : 857 858.
156. Wyeth Europa Ltd. Fachinformation Enbrel® 50 mg Fertigspritze 2007. Available at: http://www.fachinfo.de/data/fi/jsearch?praep.
157. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 96 : 146 151.
158. Partsch G, Steiner G, Leeb BF et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997 24 : 518 523.
159. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004 199 : 731 736.
160. Leibovich SJ, Polverini PJ, Shepard HM et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987 329 : 630 632.
161. MacDermott RP. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 1996 31 : 907 916.
162. Matsuno H, Yudoh K, Katayama R et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002 41 : 329 337.
163. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995 7 : 251 259.
164. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003 124 : 1774 1785.
165. Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004 53 : 70 77.
166. Smeets TJ, Kraan MC, van Loon ME et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003 48 : 2155 2162.
167. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005 64 : 1150 1157.
168. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 357 : 1842 1847.
169. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 542.
170. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 1374.
171. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002 46 : 886 891.
172. Smith CH, Jackson K, Bashir SJ et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006 155 : 160 169.
173. Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005 152 : 954 960.
174. Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006 154 : 1161 1168.
175. Reich K, Nestle FO, Wu Y et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007 17 : 381 386.
176. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 608. (Pubitemid 36204954)
177. Centocor, Inc. Data on file, Module 2.7.4 summary of clinical safety. Psoriasis BLA 2006; pp. 207, 209, 219.
178. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003 48 : 3013 3022.
179. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005 25 : 1181 1192.
180. Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 2003 62 (Suppl. 2 ii34 36.
181. Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004 99 : 2385 2392.
182. Roberts L, McColl GJ. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 2004 34 : 687 693.
183. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004 27 : 307 324.
184. Mazurek GH, Jereb J, Lobue P et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005 54 : 49 55.
185. (CDC). C. f. D. C. a. P. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004 53 : 683 686.
186. European Medicines Agency. Stelara, European Public Assessment Report. EPARs for authorised medicinal products for human use. 2009. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/stelara/stelara.htm.
187. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 345 : 248 255.
188. Krueger GG, Papp KA, Stough DB et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 47 : 821 833.
189. Gribetz CH, Blum R, Brady C et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005 53 : 73 75.
190. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003 17 (Suppl. 2 12 16.
191. Lowe NJ, Gonzalez J, Bagel J et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003 42 : 224 230.
192. Ortonne JP, Khemis A, Koo JY et al. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005 19 : 556 563.
193. Perlmutter A, Cather J, Franks B et al. Alefacept revisited: our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008 58 : 116 124.
194. Genentech, Inc. Efalizumab information sheet. 2005.
195. Jullien D, Prinz JC, Langley RG et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004 208 : 297 306.
196. Dubertret L, Sterry W, Bos JD et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 155 : 170 181. (Pubitemid 43876411)
197. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama 2003 290 : 3073 3080.
198. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 349 : 2004 2013.
199. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005 52 : 425 433.
200. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005 141 : 31 38.
201. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001 45 : 665 674.
202. Papp KA, Bressinck R, Fretzin S et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006 45 : 605 614.
203. Gottlieb AB, Gordon KB, Lebwohl MG et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004 3 : 614 624.
204. Papp KA, Miller B, Gordon KB et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006 54 : S164 S170.
205. Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000 42 : 428 435.
206. Menter A, Kosinski M, Bresnahan BW et al. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004 3 : 27 38.
207. Genentech, Inc. Important drug warning regarding raptiva® (efalizumab). 2008. Available at: http://www.gene.com/gene/products/information/ pdf/raptiva-dhcp-pml2.pdf.
208. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006 5 : 197 209.
209. Carey W, Glazer S, Gottlieb AB et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 54 : S171 S181.
210. Serono Europe Ltd. Fachinformation Raptiva 100 mg/ml 2007. Available at: http://www.fachinfo.de/data/fi/jsearch?praep.
211. Gisondi P, Giglio MD, Girolomoni G. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. J Dermatolog Treat 2006 17 : 172 175.
212. Honigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001 26 : 343 350. (Pubitemid 34204349)
213. Yano K, Kadoya K, Kajiya K et al. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 2005 152 : 115 121.
214. Holzle E, Honigsmann H, Rocken M et al. [Recommendations for phototherapy and photochemotherapy]. J Dtsch Dermatol Ges 2003 1 : 985 997.
215. Bonis B, Kemeny L, Dobozy A et al. 308 nm UVB excimer laser for psoriasis. Lancet 1997 350 : 1522.
216. Dover JS, McEvoy MT, Rosen CF et al. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 1989 20 : 748 754.
217. Ring J, Kowalzick L, Christophers E et al. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol 2001 144 : 495 499.
218. Coven TR, Burack LH, Gilleaudeau R et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997 133 : 1514 1522.
219. Orfanos CE, Steigleder GK, Pullmann H et al. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 1979 59 : 241 244.
220. Petrozzi JW. Topical steroids and UV radiation in psoriasis. Arch Dermatol 1983 119 : 207 210.
221. Ramsay CA, Schwartz BE, Lowson D et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000 200 : 17 24.
222. Arnold WP, van Andel P, de Hoop D et al. A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths. Br J Dermatol 2001 145 : 352 354.
223. Gordon PM, Diffey BL, Matthews JN et al. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999 41 : 728 732.
224. Grundmann-Kollmann M, Ludwig R, Zollner TM et al. Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol 2004 50 : 734 739.
225. Leenutaphong V, Nimkulrat P, Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 2000 16 : 202 206.
226. Markham T, Rogers S, Collins P. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003 139 : 325 328.
227. Snellman E, Klimenko T, Rantanen T. Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Derm Venereol 2004 84 : 132 137.
228. Cameron H, Yule S, Moseley H et al. Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service. Br J Dermatol 2002 147 : 957 965.
229. Koek MB, Buskens E, Bruijnzeel-Koomen CA et al. Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists. Br J Dermatol 2006 154 : 701 711.
230. Hacker SM, Rasmussen JE. The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol 1992 128 : 853 855.
231. Katugampola GA, Rees AM, Lanigan SW. Laser treatment of psoriasis. Br J Dermatol 1995 133 : 909 913.
232. Taibjee SM, Cheung ST, Laube S et al. Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol 2005 153 : 960 966.
233. Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 2002 47 : 701 708.
234. Feldman SR, Mellen BG, Housman TS et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002 46 : 900 906.
235. Housman TS, Pearce DJ, Feldman SR. A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat 2004 15 : 94 97.
236. Asawanonda P, Anderson RR, Chang Y et al. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 2000 136 : 619 624.
237. Kollner K, Wimmershoff MB, Hintz C et al. Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis. Br J Dermatol 2005 152 : 750 754.
238. Torras H, Aliaga A, Lopez-Estebaranz JL et al. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat 2004 15 : 98 103.
239. Barth J, Dietz O, Heilmann S et al. [Photochemotherapy by 8-methoxypsoralen and UVA in psoriasis vulgaris - clinical experiences in 5 dermatological departments of GDR (author's transl) ]. Dermatol Monatsschr 1978 164 : 401 407.
240. Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 1994 10 : 217 220.
241. Buckley DA, Healy E, Rogers S. A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. Br J Dermatol 1995 133 : 417 422.
242. Calzavara-Pinton P, Ortel B, Carlino A et al. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1992 1 : 46 51.
243. Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992 127 : 392 395.
244. Cooper EJ, Herd RM, Priestley GC et al. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 2000 25 : 111 114.
245. Diette KM, Momtaz TK, Stern RS et al. Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis. Arch Dermatol 1984 120 : 1169 1173.
246. Hanke CW, Steck WD, Roenigk HH Jr. Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol 1979 115 : 1074 1077.
247. Khurshid K, Haroon TS, Hussain I et al. Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV. Int J Dermatol 2000 39 : 865 867.
248. Kirby B, Buckley DA, Rogers S. Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis. Br J Dermatol 1999 140 : 661 666.
249. Park YK, Kim HJ, Koh YJ. Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol 1988 15 : 68 71.
250. Parker S, Coburn P, Lawrence C et al. A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 1984 110 : 215 220.
251. Parrish JA, Fitzpatrick TB, Tanenbaum L et al. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974 291 : 1207 1211.
252. Rogers S, Marks J, Shuster S et al. Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1979 1 : 455 458.
253. Vella Briffa D, Rogers S, Greaves MW et al. A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clin Exp Dermatol 1978 3 : 339 347.
254. Henseler T, Wolff K, Honigsmann H et al. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1981 1 : 853 857.
255. Calzavara-Pinton PG, Ortel B, Honigsmann H et al. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 1994 189 : 256 259.
256. Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993 3 : 351 354.
257. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991 127 : 347 350.
258. McBride SR, Walker P, Reynolds NJ. Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 2003 149 : 1259 1265.
259. Belsito DV, Kechijian P. The role of tar in Goeckerman therapy. Arch Dermatol 1982 118 : 319 321.
260. LeVine MJ, Parrish JA. The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol 1982 78 : 157 159.
261. Frost P, Horwitz SN, Caputo RV, Berger SM. Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation. Arch Dermatol 1979 115 : 840 846.
262. Koo JY, Lowe NJ, Lew-Kaya DA et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000 43 : 821 828.
263. Calzavara-Pinton P. Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol 1998 38 : 687 690.
264. Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA. Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol 1984 11 : 441 447.